AU Patent

AU2025201349A1 — Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Assigned to Amgen Inc · Expires 2025-03-20 · 1y expired

What this patent protects

P0032259AUD1 ABSTRACT The present invention provides combination therapy that includes an KRASG1 2C N F OH Me N N F inhibitor, such as N, or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatme…

USPTO Abstract

P0032259AUD1 ABSTRACT The present invention provides combination therapy that includes an KRASG1 2C N F OH Me N N F inhibitor, such as N, or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. 5 The invention also relates to pharmaceutical compositions that contain an KRASG1 2C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

Drugs covered by this patent

Patent Metadata

Patent number
AU2025201349A1
Jurisdiction
AU
Classification
—
Expires
2025-03-20
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.